PHM 321 Exam Obvious Questions and Correct Verified
Answers
Clinical Consequences of alpha1 adrenorecpetor activation include: - ANS Mydriasis
Pilocarpine (SALAGEN) is: - ANS a muscarinic receptor agonist
The idea of spare receptors comes from evidence that: - ANS For full agonists EC50 is less
than KD50
Nicotinic Cholinergic receptors and muscarinic cholinergic receptors - ANS are activated
by acetylcholine
A drug which binds and activates receptors but can not produce the Maximal Response
through activation of those receptors - ANS is a partial agonist
Kd of a drug is: - ANS Defined as the concentration of drug at which 50% of the receptors in a
given population will each be bound by a molecule of the drug (with the remaining receptors
being unoccupied by drug)
In consideration of production of a particular therapeutic effect, Drug X, Drug Y, Drug Z are
effective. For this therapeutic effect, the ED50 of drug X is 0.01mg , the ED50 of drug Y is 1mg
and the ED50 f drug z is 100mg. Based on this information, you can conclude that: - ANS Drug
x is the most potent of the three drugs in terms of producing this therapeutic effect.
You are given the same oral dose of a drug every 24 hours. By the sixth day the drug seems
to have reduced effectiveness (compared to its effect on the first couple of days) This
reduced effectiveness could be a result of: - ANS increased elimination
Renin Secretion: - ANS Increases renal Na and water retention and increases blood pressure
, The bioavailability of a drug administered orally ( and swallowed) is 0.05. Given this
information, you conclude that for an orally administered dose of this drug: - ANS This drug
will likely have insignificant adverse side effects if those effects require the drug to enter the
systemic circulation
Skeletal Muscle weakness can be produced by: - ANS Neostigmine(PROSTIGMIN),
Atracurium(TRACURIUM), Curare(TUBARINE)
Drug A has a t1/2 value which is half the t1/2 value of DrugB. In comparing the use of these
drugs, it is likely that Drug A: - ANS Will be given more frequently than Drug B (to achieve the
same state plasma concentration)
Theraputic use of cholinesterase inhibitors includes administration to: - ANS Increase bladder
activity in women with postpartum bladder atony and lower intraocular pressure in the eye
of patients with glaucoma
Men taking antagonists at beta1 adrenoreceptors chronically: - ANS develop erectile
dysfunction as a common side effect
Propranolol (INDERAL) is: - ANS a beta adrenergic receptor antagonist
Dopamine is produced in norepinephrine secreting neurons (including postganglionic
sympathetic neurons) as a step in the synthesis of norepinephrine.Dopamine: - ANS will
cause decreased blood pressure though activation of dopaminergic receptors in blood vessels
Drug A is administered repeatedly with a constant interval between consecutive doses and
with a constant dose. The mean plasma concentration of Drug A is measured. This
concentration: - ANS is dependent on the clearance volume for the drug
Antagonists at beta2 receptors in coronary vessels of normal individuals will as a direct effect
in these vessels: - ANS reduce blood flow to ventricular muscle
Answers
Clinical Consequences of alpha1 adrenorecpetor activation include: - ANS Mydriasis
Pilocarpine (SALAGEN) is: - ANS a muscarinic receptor agonist
The idea of spare receptors comes from evidence that: - ANS For full agonists EC50 is less
than KD50
Nicotinic Cholinergic receptors and muscarinic cholinergic receptors - ANS are activated
by acetylcholine
A drug which binds and activates receptors but can not produce the Maximal Response
through activation of those receptors - ANS is a partial agonist
Kd of a drug is: - ANS Defined as the concentration of drug at which 50% of the receptors in a
given population will each be bound by a molecule of the drug (with the remaining receptors
being unoccupied by drug)
In consideration of production of a particular therapeutic effect, Drug X, Drug Y, Drug Z are
effective. For this therapeutic effect, the ED50 of drug X is 0.01mg , the ED50 of drug Y is 1mg
and the ED50 f drug z is 100mg. Based on this information, you can conclude that: - ANS Drug
x is the most potent of the three drugs in terms of producing this therapeutic effect.
You are given the same oral dose of a drug every 24 hours. By the sixth day the drug seems
to have reduced effectiveness (compared to its effect on the first couple of days) This
reduced effectiveness could be a result of: - ANS increased elimination
Renin Secretion: - ANS Increases renal Na and water retention and increases blood pressure
, The bioavailability of a drug administered orally ( and swallowed) is 0.05. Given this
information, you conclude that for an orally administered dose of this drug: - ANS This drug
will likely have insignificant adverse side effects if those effects require the drug to enter the
systemic circulation
Skeletal Muscle weakness can be produced by: - ANS Neostigmine(PROSTIGMIN),
Atracurium(TRACURIUM), Curare(TUBARINE)
Drug A has a t1/2 value which is half the t1/2 value of DrugB. In comparing the use of these
drugs, it is likely that Drug A: - ANS Will be given more frequently than Drug B (to achieve the
same state plasma concentration)
Theraputic use of cholinesterase inhibitors includes administration to: - ANS Increase bladder
activity in women with postpartum bladder atony and lower intraocular pressure in the eye
of patients with glaucoma
Men taking antagonists at beta1 adrenoreceptors chronically: - ANS develop erectile
dysfunction as a common side effect
Propranolol (INDERAL) is: - ANS a beta adrenergic receptor antagonist
Dopamine is produced in norepinephrine secreting neurons (including postganglionic
sympathetic neurons) as a step in the synthesis of norepinephrine.Dopamine: - ANS will
cause decreased blood pressure though activation of dopaminergic receptors in blood vessels
Drug A is administered repeatedly with a constant interval between consecutive doses and
with a constant dose. The mean plasma concentration of Drug A is measured. This
concentration: - ANS is dependent on the clearance volume for the drug
Antagonists at beta2 receptors in coronary vessels of normal individuals will as a direct effect
in these vessels: - ANS reduce blood flow to ventricular muscle
